Evolving Paradigms in Lung Cancer
14th - 15th Jul 2026, 11:00pm (GMT)
Free, Online
Emerging Evidence in Non-Small Cell Lung Cancer
29th Jul 2026, 5:00pm (GMT)
Redefining RRMM Care | Interactive Roundtable
6th - 7th Aug 2026, 11:00pm (GMT)
From Signal to Action: Understanding Biomarkers in Real-World Bladder Cancer Care
Duration: 19m 34s
6 days ago
Aligned Care in Bladder Cancer - Module 3: Advanced/Metastatic Urothelial Carcinoma - Systemic Therapy and Follow-Up
Duration: 28m 43s
Aligned Care in Bladder Cancer - Module 2: Muscle-Invasive Bladder Cancer - Curative Intent Pathways
Duration: 25m 58s
Aligned Care in Bladder Cancer - Module 1: High-Risk NMIBC - Treatment Escalation Decisions
Duration: 36m 48s
From Ideal to Real: Making Guideline-Based Treatment Decisions for Bladder Cancer in Every Care Setting
17th - 18th Jun 2026, 11:00pm (GMT)
Série Synergy sur le mCRPC: La résistance aux inhibiteurs de la voie du récepteur des androgènes dans le mCRPC - Infographie
Resistencia al inhibidor de la vía del receptor de andrógenos en el cáncer de próstata resistente a la castración metastásico (CPRCm) - Infografía
mCRPC Synergy-Serie - Resistenz gegen Androgenrezeptor-Signalweg-Inhibitoren (ARPI) bei mCRPC - Infografik
Bladder Cancer Advocacy Network (BCAN) - Patient Educational Materials Flyer
Added 25 Mar 2026
Personalized Pathways: Confidence and Coordination in Biomarker-Guided Muscle-Invasive Bladder Cancer Care
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways - Synergy Snapshot
Personalized Pathways Podcast: Confidence and Coordination in Biomarker-Guided Muscle-Invasive Bladder Cancer Care
Duration: 35m 28s
3 months ago
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 - Patient Perspective
Duration: 15m 35s
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 | Part 2: Coordinating ctDNA Testing Across the Care Continuum
Duration: 17m 58s
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 | Part 3: Applying ctDNA Results to Guide Individualized Care
Duration: 15m 2s
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 | Part 1: Understanding the Dual Role of ctDNA
Duration: 15m 7s
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways - Patient Perspective
Duration: 17m 45s
